BTIG Maintains Buy on Evolent Health, Lowers Price Target to $10
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.